
James B Bussel MD
Professor of Pediatrics, Cornell University-Weill Medical College
Join to view full profile
525 E 68th St# P-695New York, NY 10065
Phone+1 212-746-3400
Fax+1 212-746-3988
Dr. Bussel is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1980 - 1981
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1975 - 1978
Columbia University Vagelos College of Physicians and SurgeonsClass of 1975
Certifications & Licensure
NY State Medical License 1978 - 2028
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2014, 2016-2017
- America's Top Doctors Castle Connolly, 2002-2014
Clinical Trials
Publications & Presentations
PubMed
- American Society of Hematology 2026 Guidelines for Immune Thrombocytopenia (ITP): Initial and Second-Line Therapy in Adults with Primary ITP.Adam Cuker, Deirdra R Terrell, Honieh Sowdagar, Donald M Arnold, Sylvain Audia
Blood Advances. 2026-08-19 - Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Sur...Nichola Cooper, James Bussel, Waleed Ghanima, Drew Provan, Yoshiaki Tomiyama
American Journal of Hematology. 2026-08-01 - BCMA-directed CAR-T cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia.Jinhui Shu, Min Xu, Peiru Li, Wei Xie, Lin Liu
Blood. 2026-07-24
Abstracts/Posters
- The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP SurveyJames B. Bussel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerabil...James B. Bussel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- PhysiciansÍ and PatientsÍ Perspectives on Treatments in ITP _ a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISh)James B. Bussel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Potentiating the Power of Platelets: Examining the Clinical Utility of Multiple Thrombopoietin Receptor Agonists in ITP, Chemotherapy Induced Thrombocytopenia and Live...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Platelets 2012 International SymposiumJonathan Wood & Associates, Beverly, Massachusetts - 6/7/2012
Other
- Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in childrenBussel JB
http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-immune-thrombocytopenia-it
UpToDate, Wolters Kluwer Health - 2013-03-29
Press Mentions
- Dramatic Increase in Response with Combination for Relapsed/Resistant ITPJanuary 28th, 2022
- Adding Mycophenolate Mofetil Improves Outcomes in ITPSeptember 1st, 2021
- The Faces I’ll Remember, Long After I Put My Notebook DownJune 18th, 2021
Grant Support
- Novel Therapies In Hemostasis And TransfusionNational Heart, Lung, And Blood Institute2007–2009
- Novel Therapies In Hemostasis And Transfusion MedicineNational Heart, Lung, And Blood Institute2002–2006
- Rituxan Comparison Standard VS Combination With CVP In ITPNational Center For Research Resources2005
- OPEN Label, Phase I/II Trial Of Rituximab For Chronic, Severe, Idiopathic ThromNational Center For Research Resources2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









